Terms: = Liver cancer AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Clinical Outcome
394 results:
1. Comparison of Microwave and Radiofrequency Ablation for the Treatment of Small- and Medium-Sized Hepatocellular Carcinomas in a Prospective Randomized Trial.
Vogl TJ; Martin SS; Gruber-Rouh T; Booz C; Koch V; Nour-Eldin NA; Hussainy Said MN
Rofo; 2024 May; 196(5):482-490. PubMed ID: 38065541
[TBL] [Abstract] [Full Text] [Related]
2. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
Saberzadeh-Ardestani B; Jones JC; McWilliams RR; Tougeron D; Halfdanarson TR; Guimbaud R; Hubbard JM; Flecchia C; Shi Q; Alouani E; Sonbol MB; Ticku J; Jin Z; Taieb J; Sinicrope FA
Eur J Cancer; 2024 Jan; 196():113433. PubMed ID: 37979306
[TBL] [Abstract] [Full Text] [Related]
3. Exploration and validation of a novel signature of seven necroptosis-related genes to improve the clinical outcome of hepatocellular carcinoma.
Tao Q; Lang Z; Li Y; Gao Y; Lin L; Yu Z; Zheng J; Yu S
BMC Cancer; 2023 Oct; 23(1):1029. PubMed ID: 37875823
[TBL] [Abstract] [Full Text] [Related]
4. Optimal Follow-up of Incidental Pancreatic Cystic Lesions without Worrisome Features: clinical outcome after Long-term Follow-up.
Ahn DW; Lee SH; Choi JH; Cho IR; Jang DK; Paik WH; Jeong JB; Ryu JK; Kim YT
Gut Liver; 2024 Mar; 18(2):328-337. PubMed ID: 37840221
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of Baseline
Wu M; Wang Y; Yang Q; Wang X; Yang X; Xing H; Sang X; Li X; Zhao H; Huo L
J Nucl Med; 2023 Oct; 64(10):1532-1539. PubMed ID: 37500263
[TBL] [Abstract] [Full Text] [Related]
6. The Feasibility, Proficiency, and Mastery Learning Curves in 635 Robotic Pancreatoduodenectomies Following a Multicenter Training Program: "Standing on the Shoulders of Giants".
Zwart MJW; van den Broek B; de Graaf N; Suurmeijer JA; Augustinus S; Te Riele WW; van Santvoort HC; Hagendoorn J; Borel Rinkes IHM; van Dam JL; Takagi K; Tran KTC; Schreinemakers J; van der Schelling G; Wijsman JH; de Wilde RF; Festen S; Daams F; Luyer MD; de Hingh IHJT; Mieog JSD; Bonsing BA; Lips DJ; Abu Hilal M; Busch OR; Saint-Marc O; Zeh HJ; Zureikat AH; Hogg ME; Koerkamp BG; Molenaar IQ; Besselink MG;
Ann Surg; 2023 Dec; 278(6):e1232-e1241. PubMed ID: 37288547
[TBL] [Abstract] [Full Text] [Related]
7. Factors predictive of clinical outcome in advanced hepatocellular carcinoma patients receiving ramucirumab treatment: A real-world experience.
Lin PT; Hung MH; Shao SC; Chen HY; Chan YY; Chang KC; Lin SM; Ou HT
Cancer Med; 2023 Jul; 12(14):14902-14911. PubMed ID: 37278402
[TBL] [Abstract] [Full Text] [Related]
8. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer.
Inkoom A; Ndemazie NB; Smith T; Frimpong E; Bulusu R; Poku R; Zhu X; Han B; Trevino J; Agyare E
BMC Cancer; 2023 May; 23(1):435. PubMed ID: 37179357
[TBL] [Abstract] [Full Text] [Related]
9. Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer.
Ortiz-Barahona V; Soler M; Davalos V; García-Prieto CA; Janin M; Setien F; Fernández-Rebollo I; Bech-Serra JJ; De La Torre C; Guil S; Villanueva A; Zhang PH; Yang L; Guarnacci M; Schumann U; Preiss T; Balaseviciute U; Montal R; Llovet JM; Esteller M
Mol Cancer; 2023 May; 22(1):83. PubMed ID: 37173708
[TBL] [Abstract] [Full Text] [Related]
10. A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation.
Yang Z; Xie H; Wan J; Wang Y; Zhang L; Zhou K; Tang H; Zhao W; Wang H; Song P; Zheng S
EBioMedicine; 2023 Jun; 92():104594. PubMed ID: 37167784
[TBL] [Abstract] [Full Text] [Related]
11. Prediction of liver-Related Events With a Combination of liver Stiffness Measurements and Controlled Attenuation Parameters in Japanese Patients With Biopsy-Proven Non-alcoholic Fatty liver Disease.
Hayashi H; Kamada Y; Fujii H; Takahashi H; Oeda S; Iwaki M; Kawaguchi T; Tomita E; Yoneda M; Tokushige A; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
Ultrasound Med Biol; 2023 Jul; 49(7):1658-1664. PubMed ID: 37120329
[TBL] [Abstract] [Full Text] [Related]
12. clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
[TBL] [Abstract] [Full Text] [Related]
13. Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in hepatocellular carcinoma microenvironment.
Yin Z; Ma T; Chen S; Yu M
Cancer Biomark; 2023; 36(3):231-250. PubMed ID: 36938723
[TBL] [Abstract] [Full Text] [Related]
14. [Sero-epidemiological characteristics of the hepatitis D virus infection among hepatitis B virus infected-patients at a single center in Xinjiang region].
Zheng RJ; Talafu T; Deng ZR; Han D; Pan KJ; Lu XB
Zhonghua Gan Zang Bing Za Zhi; 2022 Oct; 30(10):1044-1049. PubMed ID: 36727249
[No Abstract] [Full Text] [Related]
15. The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: A sigh of relief?
Waissengrin B; Leshem Y; Taya M; Meiri D; Merimsky O; Shamai S; Wolf I; Rubinek T
Eur J Cancer; 2023 Feb; 180():52-61. PubMed ID: 36535195
[TBL] [Abstract] [Full Text] [Related]
16. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
[TBL] [Abstract] [Full Text] [Related]
17. Prediction of Protumorigenic Effects after Image-Guided Radiofrequency Ablation of Hepatocellular Carcinoma Using Biomarkers.
Stechele M; Wildgruber M; Markezana A; Kästle S; Öcal E; Kimm MA; Alunni-Fabbroni M; Paldor M; Haixing L; Salvermoser L; Pech M; Powerski M; Galun E; Ricke J; Goldberg SN
J Vasc Interv Radiol; 2023 Sep; 34(9):1528-1537.e1. PubMed ID: 36442741
[TBL] [Abstract] [Full Text] [Related]
18. [Real-world data analysis of 3012 patients undergoing laparoscopic radical gastrectomy in a single center over the past 12 years].
Wang LJ; Li Z; Wang S; Liu HD; Li QY; Li BW; Xu JH; Ge H; Wang WZ; Li FY; He ZY; Zhang DC; Xu H; Yang L; Xu ZK
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Aug; 25(8):716-725. PubMed ID: 35970806
[No Abstract] [Full Text] [Related]
19. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract] [Full Text] [Related]
20. Head-to-Head Comparison of [
Wegen S; van Heek L; Linde P; Claus K; Akuamoa-Boateng D; Baues C; Sharma SJ; Schomäcker K; Fischer T; Roth KS; Klußmann JP; Marnitz S; Drzezga A; Kobe C
Mol Imaging Biol; 2022 Dec; 24(6):986-994. PubMed ID: 35771317
[TBL] [Abstract] [Full Text] [Related]
[Next]
